Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jyoti Prabhu"'
Autor:
Aruna Korlimarla, PS Hari, Jyoti Prabhu, Chanthirika Ragulan, Yatish Patil, VP Snijesh, Krisha Desai, Aju Mathews, Sandhya Appachu, Ravi B. Diwakar, BS Srinath, Alan Melcher, Maggie Cheang, Anguraj Sadanandam
Publikováno v:
Translational Oncology, Vol 27, Iss , Pp 101574- (2023)
Externí odkaz:
https://doaj.org/article/8af7d49800d6483188b46b69120e86c7
Autor:
Aruna Korlimarla, Hari PS, Jyoti Prabhu, Chanthirika Ragulan, Yatish Patil, Snijesh VP, Krisha Desai, Aju Mathews, Sandhya Appachu, Ravi B. Diwakar, Srinath BS, Alan Melcher, Maggie Cheang, Anguraj Sadanandam
Publikováno v:
Translational Oncology, Vol 25, Iss , Pp 101511- (2022)
Purpose: Triple-negative breast cancer (TNBC) is a heterogeneous disease with a significant challenge to effectively manage in the clinic worldwide. Immunotherapy may be beneficial to TNBC patients if responders can be effectively identified. Here we
Externí odkaz:
https://doaj.org/article/a88adf8242244906823d8dcfed4bdb5f
Autor:
Jyoti Prabhu, Kiran Abhijit Kulkarni, Elizabeth Vallikad, Gayatri Ravikumar, Savitha Rajarajan, Julian Crasta, Sumangala Gali
Publikováno v:
International Journal of Gynecological Pathology. 40:49-55
Human epidermal growth factors play an important role in ovarian carcinogenesis and are evaluated for prognostic and possible therapeutic roles in high-grade serous ovarian malignancies. The present study was undertaken to evaluate the expression of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::701c04942754e49248a5da485762b69c
https://doi.org/10.1097/pgp.0000000000000678
https://doi.org/10.1097/pgp.0000000000000678
Autor:
Aruna Korlimarla, PS Hari, Jyoti Prabhu, Chanthirika Ragulan, Yatish Patil, VP Snijesh, Krisha Desai, Aju Mathews, Sandhya Appachu, Ravi B. Diwakar, BS Srinath, Maggie Cheang, Anguraj Sadanandam
BackgroundTriple-negative breast cancer (TNBC) is a heterogeneous disease with a significant clinical challenge. TNBC alarmingly comprises 25-30% of breast cancers in India compared with only 10-15% in the West. However, immunotherapy was approved fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::41218f739a5fc7fe90eebb5dd0d0ac59
https://doi.org/10.1101/2022.03.06.483159
https://doi.org/10.1101/2022.03.06.483159
